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Smokeless Tobacco dependence and cessation measures in India         
India being the largest smokeless tobacco (SLT) producer and 
consumer in the South East Asia Region (SEAR) entitled with a 
range of products. SLT consumption is very common because 
it is associated with socio-economic and cultural perspectives 
in the India. After the implementation of the first treaty of the 
World Health Organization Framework Convention on Tobacco 
Control (WHO-FCTC), public health standards were reaffirmed 
and improvised through successful implementation of articles 
since 2007 as reported in the global progress factsheet. Many 
measures have been implemented for achieving the success of 
WHO-FCTC in India and to control the huge disease burden in-
duced by tobacco use. The objective of the present study was to 
understand and explore the factors involved in the SLT demand 
reduction by revealing the dependence and cessation implemen-
tation in India in the context of strategies and policies. For this 
study, we searched for SLT dependence and SLT cessation liter-
ature survey in PubMed and obtained 102 literatures consisting 
of studies and reviews, which were further scrutinized by exclud-
ing the reviews, studies conducted abroad and studies conduct-
ed within the last 5 years (after 2015). No statistical significance 
was observed in comparison of National to International SLT 
dependence and an attempt to quit SLT following the tenure of 
a year. This is in-line with GATS-2 and international data. We 
have also discussed a diverse approach in the control of SLT at 
different levels-such as SLT users, healthcare professional, pol-
icy advocates supplier, labeling, legal policies, and educating at 
various platforms. Effective strategies for the cessation of SLT is 
mandatory with proper guidance for the manufacturer, users and 
sellers in controlling SLT products.
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Highlights: 
1. COP3 act implemented for tobacco demand 
reduction in India. 
2. Behavioral intervention is considered as an ef-
fective for SLT cessation. 
3. Indian and International policies needs addi-
tional tool in controlling SLT demand. 
4. Prevailing gap in adopting WHO-FCTC arti-
cles in governance of Indian SLT products. 
 
Introduction 
According to WHO-FCTC report, India is the 
third-largest tobacco producer globally, with the 
tobacco consumer capacity of 32.9% and 18.4% 
for chewing (SLT), and 24.3% and 2.9% for 
smoking 1 in males and females, respectively. 
Though SLT usage is high in India, the control-
ling measures and policies are not as effectively 
implemented as the policies for cessation of 
smoked tobacco (cigarette). SLT available in 
many forms, some are chewable tobacco: 
khaini, zarda, kiwam, gundi, betel quid with to-
bacco; areca nut with tobacco chewable: gutka, 
manipuri, mawa, dohra, beeda; applying to-
bacco: gudhaku, gul, creamy snuff, lal dantman-
jan, mishri/masher; gaggling/sipping tobacco: 
tuibur, hidakphu, liquid form tobacco; and inhal-
ing tobacco: snuff. SLT or any form of tobacco is 
a major leading cause for treatable diseases and 
death with an estimated 6.3 million victims yearly 
2. Similarly, 8 million deaths are estimated due to 
tobacco consumption by 2030 in low and middle-
income countries 3.  
In the GATS-2 report on India (2016-2017), SLT 
users are approximately two-fold higher than the 
smokers (99.5 million). Also, the SLT users in In-
dia have reduced around 20% compared with 
the 2010 report. To reach the FCTC objective, 
intensifying measures have been detailed in the 
tobacco control program, as gutka and pan ma-
sala banned by Supreme court in 2004 and 
brought under a legal act-2.3.4 under Food 
Safety and Standards Act (FSSAI), 2006 3, 4. Be-
ing an active synchronized member of WHO-
FCTC, India has enforced rules and regulations 
on production, supply, sale of tobacco products, 
distribution, advertisement, prohibition of sale 
near to educational centers, etc. through Minis-
try of Law and Justice (2003), Cigarette and 
Other Tobacco Products Act (COTPA) 3, 5. India 
felt difficulty in the control of tobacco (SLT) be-
cause of regional complexity and being the sec-
ond-largest consuming country (Males: 32.9%, 
Females: 18.4%) in SEAR 1. In maintaining the 
socio-economic and cultural status, the attitude 
of SLT consumption is unrestrained, hence it is 
stringently intertwined in Indian practice.  
The vast varieties of the SLT are scientifically 
proven with high addiction in the Indian culture 
similar to smoked tobacco products. The present 
scenario of the SLT products worsen the health 
status and addiction, and points to tough chal-
lenges in the global implementation of regula-
tions. WHO-FCTC is an authenticated and relia-
ble party to look after the control of all tobacco 
products (smoked tobacco and SLT) burden. 
The unresolved SLT issue combined with the 
lack of data globally leads to a delay in the im-
plementation of the FCTC policy. Guidelines that 
are aimed at emphasizing the adaptation of 
FCTC demand reduction measures and cessa-
tion policies and requested the convention sec-
retariat to maintain a database of parties, imple-
mentation reports and other international 
sources 6, 7. India has created 429 cessation fa-
cilities across the country functioning under the 
National Tobacco Control Programme (NTCP) 
and few community cessation clinics. Further-
more, India 8 and Thailand developed national 
tobacco cessation manuals in different regional 
languages. Additionally, NTCP launched tele-
phonic helplines in trying to establish tobacco 
cessation at the national and district levels 8, 9. 
WHO-SEARO developed the following manuals 
in tobacco control and cessation at the 
healthcare provider level: 
a) Helping People Quit Tobacco: A Manual for 
Doctors and Dentists. 
b) Tobacco Cessation: A Manual for Nurses, 
Health Workers and Other Health Profes-
sionals. 
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c) Manual on Tobacco Control in Schools. 
d) Community Cessation Manual. 
In order to address the tobacco burden associ-
ated with cancer incidence, many workshops 
were conducted by the Institute of Medicine 
(IOM) for the National Cancer Policy Forum 
along with suggested guidance for cancer treat-
ment; tobacco dependence and cessation pro-
grams. Furthermore, the federal and state level 
laws and regulations in controlling tobacco use 
through the medium of tobacco control educa-
tion; message and advocacy were implemented. 
Finally, the financial and legal challenges to to-
bacco control were overcome by expanding the 
infrastructure of tobacco control strategies 10. 
Similarly, the U.S. Department of Health and Hu-
man Services (USDHHS) conducted tobacco 
cessation programs and derived outcomes of 
nicotine replacement therapy (NRT) and pro-
vided NRT products (gum, patches or lozenges); 
interviewed assessment over the phone; cus-
tomized quit plans; executing counselling ser-
vice; biweekly follow-up calls for successful im-
plementation of strategies; conducting an online 
survey every six months for the readiness of quit 
plan to ensure the success of the program. 
The robust consumption of SLT products in India 
requires effective control and implementation 
through all types of legislative measures like pro-
duction, supply, distribution, consumer, pricing, 
sale and taxation. Moreover, WHO-Global Ac-
tion Plan has set a goal of 30% relative reduction 
in current tobacco use frequency by 2025 11. In-
dia has taken many measures in controlling to-
bacco consumption (smoking and SLT) through 
laws (COTPA, 2003), but still need some perfect 
tools and measures in tobacco cessation. Few 
are listed below: 
i) Cessation at User level 
India extends the clinic service of tobacco 
cessation through the Ministry of Health 
and Family Welfare, Government of India 
and WHO, which are now anticipated as 
a central node for National Tobacco Con-
trol Programme (NTCP). Tobacco cessa-
tion clinics (TCC) regularly register the to-
bacco user profile and document it. TCC 
set 5A’s, a list of evidence-based inter-
vention strategies, which have proven to 
be a successful tool for counselling 12. Us-
ers continue consuming SLT products 
based on the different perceptions like 
community acceptance, unawareness of 
adverse health effects, addiction, work 
environment, lack of health provider at-
tention, etc. Pratima Murthy et al carried 
out a survey on 58 Key Informants based 
on the WHO SEARO emphasized on in-
adequate knowledge on harm of SLT use 
between users and health care providers 
13. Many surveys state that users having 
a misconception about SLT having low 
health risk, a high intention of shifting be-
tween different forms of SLT products and 
low demand for SLT quit assistance. The 
results of the survey pointed out that SLT 
users resist enrolling in the list to encour-
age society to quit tobacco products. 
Specific attention cannot be created by 
targeting users by mailing, phone and ad-
vertisements on discussing quitting SLT 
products. Hence there is a need for some 
additional parameters like healthcare pro-
vider or counselor-based approach in the 
SLT cessation to users which fails other-
wise due to a lack of knowledge at the 
user level.  
ii) Cessation at Healthcare provider 
stage 
In U.S. high schools, consumption of SLT 
products by males is around13% 14, 15 as 
stated in the survey reported by CDC, 
2012. The SLT users state their psycho-
logical perception of SLT usage is “a safe 
alternative for smoking” 10. The U.S. Pub-
lic Health Service (USPHS) guide for the 
users to quit/control/cessation of tobacco 
has a success rate of 66% by engaging in 
the 5A’s strategy 16. It has instructed the 
health-care providers to apply manual 
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based practice on tobacco users by doc-
umenting, providing adequate training, 
resources, directing to counselors and 
recommending regular visits. The quitting 
tobacco counseling by health care provid-
ers is considered to be a successful inter-
vention in the tobacco controlling pro-
gram 16.  The doctors practice evaluating 
the environment and systems of tobacco 
users in a schematic process of queries 
(5A’s; Ask, Advise, Assess, Assist and Ar-
range) which are updated in the patient 
chart. Few clinicians find that 70% of 
smokers ascribe to the acceptance of 
quitting and 32% acceptance was drawn 
using evidence based counseling/ medi-
cation 17. Tobacco users are advised to 
visit at regular intervals, assistance to quit 
tobacco is provided, tobacco related ill-
nesses are assessed and regular phone 
calls are arranged, electronic health rec-
ords are created and E-visits for medical 
appointments are pursued 18. 
Tobacco cessation program directed to-
bacco users to undergo counseling medi-
ated motivational interviews to encourage 
behavior change by providing them open-
ended question sessions, tobacco cessa-
tion declaration and persuade online mo-
tivational classes through web based ap-
proach (www.motivationalinterview-
ing.org) made available 16.  Along with 
motivational interviews, users are pro-
vided a strategic plan of multiple clini-
cians, quitline specialists, practical coun-
seling and medication for tobacco cessa-
tion. US-FDA has given approved medi-
cations for smoke cessation which is an 
alternative for tobacco products like nico-
tine-based replacements (gum, lozenge, 
transdermal patch, nasal spray and in-
haler), bupropion SR and varenicline 16, 
19. Patients are motivated towards to-
bacco cessation through electronic refer-
rals, quitline and follow-up, health educa-
tion, etc. It creates patience to standard-
ize electronic health record systems to 
coordinate and advise about smoke free 
environments by tracking clinical condi-
tions 16. 
iii) Cessation at Laws and Regulation 
level 
In 2001, the European Union (EU) to-
bacco products directives enforced re-
duction of cigarette emissions and dis-
closed ingredients. It was revised for fur-
ther control of tobacco product addictions 
in 2016. These include ban on character-
ized flavors; all promotional and mislead-
ing advertisement on tobacco products; 
notifying authorities before products get 
placed in the market by manufacturers; 
new labelling and reporting requirements. 
EU directives partially adopted the WHO-
FCTC Articles 9 and 10 (Regulation of 
contents and disclosure of tobacco prod-
ucts), but still efforts are being made for 
better implementation of contents and 
disclosure of tobacco products. EU stand-
ards authorized the US-FDA regulation of 
the Family Smoking Prevention and To-
bacco Control Act, 2009 by including the 
prohibition of reduced harm tobacco 
products and banning flavoured tobacco 
products with the exception of menthol 20. 
The revised tobacco products directive 
(2014/40/EU) insisted manufacturers to 
produce the peer review report of the to-
bacco products and costs are to be borne 
by the industry 21. According to the UK To-
bacco Advertising and Promotion Act-
2010, the promotion of tobacco products 
was prohibited from all images, news, 
music videos, films or TV advertisements. 
EU directives on Regulation of the con-
tents of tobacco products (Article 9) in-
structed to display the general warning on 
the lateral side, front and back surface of 
pack/ package about the quote of quitting 
and/or picture warning of hazards of us-
ing tobacco products. At a regular interval 
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of every 5 years the quit text should be 
replaced and picture warning with proper 
scientific and market development and 
displaying the quitline help number in the 
pack/ package 21, 22. 
Considering the public health and future, 
the United States signed the Tobacco 
Control Act (Family Smoking Prevention 
and Tobacco Control Act) on June 22, 
2009 for the regulation of the manufac-
ture, distribution, and marketing of to-
bacco products 23. The act dealt with re-
strictions for marketing tobacco products 
to children, restriction for access of vend-
ing machines for children and modified 
packaging policy by reducing to 20 ciga-
rettes per packet. Furthermore, tobacco 
brand sponsorship in the field of sports, 
entertainment, etc., was banned. A ban 
was also placed on flavored cigarettes 
(except for menthol) and promotional of-
fers/ free samples were restricted. U.S. 
Food and Drug Administration Act (US-
FDA) amended the Federal Food, Drug 
and Cosmetic Act in 2019which in-
creased the minimum age to 21 for sale 
of tobacco products to adults. SLT prod-
ucts were required to be sold with ade-
quate display area (20-30%) of warning 
labels in the package and announced 
warning quotes of tobacco causes mouth 
cancer, gum disease and tooth loss; 
harmful alternative for cigarettes; induces 
addictiveness, etc. FDA optimizes the 
policy for the alternative tobacco products 
with modified risk for registration under 
section 911 of the Federal Food, Drug, 
and Cosmetic (FD&C) Act provided with 
scientific data. FDA instructed the manu-
facturer/ companies to consider section 
904(a)(1) by mentioning the ingredient list 
of the finished tobacco products. FDA re-
quires the tobacco companies to register 
annually, sets compliance standards for 
tobacco products subjected to process 
visits and inspection at every two years 
interval 24, 25.  
In India, according to the COTPA-2003 
(Control of Tobacco Products Act) and 
National Guidelines for Tobacco Cessa-
tion, survey data obtained from NFHS2 & 
3 revealed that the estimated prevalence 
rate of chewing tobacco consumption 
rose to 35.4% (men) and 18.2% (females) 
from 28.3% (men) and 12.4% (females). 
COTPA act deals with the prohibition of 
advertisement, provides guidelines and 
regulations of trade and commerce in pro-
duction, supply and distribution of To-
bacco products. After resolution of 39th 
WHO assembly, member states were 
urged to consider tobacco control strate-
gies, plans and measures for protecting 
citizens with special attention to pregnant 
women and children by rejecting direct 
and indirect advertisement, promotion 
and sponsorship towards tobacco prod-
ucts 12, 5.  
The act declares that the practice of con-
trol over the tobacco industry given direc-
tives to the state government. The policy 
encourages the creation of awareness for 
tobacco products by means of caution ad-
vertisement of tobacco use in any form 
like notice, circular, label, document or by 
oral announcement or musical, sound, 
smoke/gas display. Similarly, any kind of 
advertisement of tobacco products for the 
production, supply/ distribution in any 
mode (pamphlet, announcement, sound, 
display) is banned. The COTPA act 
strictly by prohibiting free sample supply, 
exporting tobacco products with gram-
matical variations and cognate expres-
sion for export outside India. Instructions 
are given for neat representation by writ-
ing, marking, stamp, printing, graphical 
matter on a package in any Indian re-
gional language of the corresponding re-
gion or the English language in the to-
bacco product is only accepted to be 
Ramu Venkatesan et al., IJOAR, 2020 3:68 
IJOAR: https://escipub.com/international-journal-of-aging-research/                     4
placed in the market. The access (sale, 
consuming) of tobacco products in any 
kind of public place (auditorium, hospital, 
railway waiting room, restaurants, 
amusement, public offices, court building, 
education building, libraries, public 
transport) is strictly prohibited and pun-
ishable. Tobacco product consumption in 
any public place should be physically 
separated by a closed partition; this pro-
vision is allowed by prescribing to the 
rules made under this act. Any kind of ad-
vertisement agent should be barred to 
sign the contract for promotion/ advertise-
ment of any kind of tobacco products. Us-
ing the trademark, the brand name of to-
bacco products should not be used to fa-
cilitate or sponsor any event. The sale of 
tobacco products to the students or the 
person under eighteen years of age 
should be rigorously forbidden.  
In the case of supply/ distribution of any 
tobacco products, it should display all the 
details of products with specified warning 
including pictorial depiction of skull and 
crossbones in the packet/ package panel. 
All the warning write-ups in the package/ 
packs should be legible with major known 
languages (English and/or Indian regional 
dialect or multiple language(s) along with 
English), prominent and noticeable with 
colored font size and bold. Import of to-
bacco products is a legal offense, any to-
bacco products required to show the nic-
otine and tar contents of their product and 
if suspicious, the inspection shall be car-
ried out by rank officers (Sub-inspector of 
police or any Food or Drug safety offic-
ers). When there is any noncompliance 
with COPTA, 2003, the rank officer has 
the authority to question or seize the 
product and submit it to District jurisdic-
tion court or the authority can place a fine 
in lieu of the confiscated items. In this 
junction, the affected person shall have 
the right to incline under the provisions of 
this act. In the same way, the law has 
given the facility to the owner to surrender 
a reason for confiscating within 90 days 
or can appeal to the court for judgement 
of confiscation. No further appeal can be 
made against the court order 5. Few pro-
ceedings/ offence and the punishment in 
India against the action as mentioned in 
Table 1. 
 
 
Table 1. Proceedings/ offence and the punishment in India 
Sl. No. Offense Punishment 
1.  Failure to produce/ specify warning and nicotine and tar con-
tents – First conviction 
Rs.5000/- or imprisonment for 5 years 
or both 
2.  Failure to produce/ specify warning of nicotine and tar contents 
– Second conviction 
Rs.10000/- or imprisonment for 5 years 
or both. 
3.  Person sells or distributes tobacco products with no proper la-
belling/ specified warning and nicotine and tar contents – First 
conviction 
Rs.1000/- or 1year imprisonment or 
both 
4.  Person sells or distributes tobacco products with no proper la-
belling/ specified warning and nicotine and tar contents – Sec-
ond conviction 
Rs.3000/- or 2 years imprisonment or 
both 
5.  Smoking in restricted places Rs.200/- 
6.  Advertisement of Cigarettes and tobacco products – First con-
viction 
Rs.1000/- or 2 years imprisonment 
7.  Advertisement of Cigarettes and tobacco products – Second 
conviction 
Rs.5000/- or 5 years imprisonment 
8.  Sale of cigarettes and tobacco products to below eighteen 
years age 
Rs.2000/- 
Ramu Venkatesan et al., IJOAR, 2020 3:68 
IJOAR: https://escipub.com/international-journal-of-aging-research/                      7
iv) Cessation at Self help guide – Applica-
tion 
In America, currently 22% of the SLT us-
ers are residing in towns and rural areas. 
According to the 2006 online SLT cessa-
tion program, 2523 SLT users were re-
cruited through media, google advertise-
ment, links through web sites, paid adver-
tisement, direct mailing and targeted 
mails to healthcare professionals. Users 
showed interest and smoothly paved 
ways to help them to quit, hence online 
based self help guide through links and 
guidance through applications can in-
crease the success rate of quitting SLT 
products 26.  
National Cancer Institute (NCI) funded a 
research program which tested interven-
tion programs (RTIPs) and provided infor-
mation for the self-help cessation manual 
for SLT users (both male and female) of 
all age ranges. The intervention supports 
SLT users very effectively for quitting in a 
short span of time. The program assisted 
SLT users with the booklet of cessation 
manual, education on health hazards by 
SLT products, 20 minutes of self-help 
guide videos and two supportive phone 
calls from tobacco cessation counselors 
27. Similar to RTIPs, many web-based 
self-help intervention programs appeared 
on the internet for international and na-
tional SLT users. This program collects 
data from users at sign-in level. ‘Chew-
Free.com’ is an internet-based program 
which helps SLT users by giving different 
levels of education, self-help manuals 
and videos with links for counselling and 
phone call options.  
In India, under the Ministry of Health and 
Family Welfare (MHFW), The National 
Tobacco Control Programs (NTCP) han-
dle multifaceted approaches towards the 
tobacco cessation programs. Through 
this platform, multiple notifications to im-
plement the WHO-FCTC guideline are 
proposed, along with a cessation man-
agement program and a helpline for the 
tobacco users by directing them to Quit-
line, M-cessation (SMS) and counselling 
facilities at a district level. Along with the 
NTCP, few non-governmental organiza-
tions are also arranging tobacco control 
programs 8. QuitX is a user-friendly web-
based tobacco cessation application that 
utilizes a panel of counsellors, educating 
manuals and guidelines for the SLT users 
and also collects national and interna-
tional data about the SLT users for fea-
tured surveys 28.  
v) Future perspective of Monitoring & 
Cessation 
SLT consumption associated with a lot of 
major health threats needs advance scru-
tinizing policies at various levels of ap-
proach in the production, composition, 
distribution, marketing, sales, user con-
sumption, healthcare provider and poli-
cies. Vast burden of health risk associ-
ated with SLT products cannot be de-
fended with negligible measures against 
the SLT. Interventions are poorly imple-
mented or merely neglected and execu-
tion of cessation programs is remarkably 
less effective in comparison with smoking 
tobacco. The license criteria for the man-
ufacturing, marketing, selling of SLT 
products should be tailored which in turn 
support the control of SLT and tobacco 
products 29. Prioritizing the systematic ap-
proach of SLT dependence and cessation 
through health-care providers, counse-
lors, pharmacotherapy and national quit-
lines, establishing the platform with less 
effort, cost-effective tobacco control pol-
icy and tobacco dependence treatment 
system can help the SLT users to quit at 
the earliest from the burden 6. Enhanced 
SLT cessation intervention with a ran-
domized controlled trial and cohort stud-
ies observed through multifaceted/ com-
bination approach by sequential applying 
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of above intervention programs show a 
success rate of more than 50% 30.  
Methodology 
The data for the review on the SLT dependence 
and cessation in India was collected from Pub-
Med irrespective of the period of date or obser-
vations collected from national or state-level sur-
veys. The data was scrutinized and screened for 
various parameters and the articles for reviewing 
were searched and selected for the period of 
2015 to 2020 (last 5 years). The special consid-
eration was given to screen the nicotine depend-
ence and quit attempt in SLT users and dis-
cussed. 
The strategy for selection of literature from Pub-
Med is described in Figure 1: 
Statistical analysis 
Data were analyzed in GraphPad Prism Soft-
ware version 5.01 for statistical variation in sim-
ple proportions. Statistical significance between 
two groups was analysed by Student’s t-test us-
ing GraphPad Prism software. The difference 
and pattern of SLT quit attempt/ willingness and 
dependence use are reported in percentage. A 
P value <0.05 was considered as statistically 
significant. 
 
 
Figure 1: Schematic representation of literature selection for review. 
 
Result 
Majority of the SLT dependence and cessation 
survey in India concludes with higher depend-
ence in SLT, especially from 258 respondents’ 
report of Tertiary care hospital, Bhavnagar, 
Western India identified using Fagerstrom Test 
Nicotine Dependence (FTND). The result clearly 
indicates that the SLT users have consumed va-
rieties of chewable tobacco forms such as 
mawa, vimal pan masala, zarda, khaini and 
mishri, with most consumed being higher in men 
than women. Their higher dependency of chew-
able tobacco concerned to duration is 18.92±9.7 
years, with the average age of tobacco chewing 
started in 23.31±6.45 years and the number of 
packets of chewable tobacco consumed is 
3.77±1.99 per day. Also reported in the survey 
about the higher willingness/attempt to quit SLT 
products are 38.8% of respondents with at least 
one attempt in their life 31. On the basis of the 
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questionnaire conducted with 759 participates in 
an industrial part of the Western region of India, 
the prevalence of SLT users of 28% (SLT alone) 
and 9.7% (smoking & smokeless tobacco) all fall 
in the age range of 18-54 years. Users with to-
bacco dependence score of 24% showed high-
est dependence rate with both the smoking & 
smokeless products whereas 17% of nicotine 
dependence observed in smokeless products 
predicted through FTND test (Figure 2a). The 
highest percentage (19-34%) of SLT users fall in 
the age of 21 to 45 years and 52.9% of users 
attempted to quit tobacco products at least once 
32 which is identical to the SLT quit attempt in 12 
months of GAT2, 2018 report 1 (Figure 2b).  
Mohammed et al conducted the study by using 
120 participants (60 cases leukoplakia and oral 
submucous fibrosis group and 60 control group) 
selected through dental hospitals around Chen-
nai city. The participants consumed SLT prod-
ucts such as mawa, pan masala, gutkha, khaini 
and betel quid with FTND dependency score for 
SLT products being 7.83±2.17 with usage fre-
quency per day of 5.97±1.90 number of times of 
consumption 33. Key informant’s (KI) (SLT users 
and health care providers) survey found 62% of 
KI-SLT users, majority SLT users (68%) started 
SLT consumption between 16-39 years and 
35.1% of SLT users made quitting attempts at 
least once in the past. The health care provider 
KI’s 52.3% reported awareness of tobacco ces-
sation. The major SLT products consumed by 
the SLT users were guthka, kaddipudi or 
hogesoppu. The main cause for the SLT use 
stated by KI’s are enjoyment, time-pass, habit, 
stress relief, easily availability and very feasible 
marketing strategies (available in pouches), and 
few states continue consuming to maintain so-
cial community. The awareness about the health 
adverse effect by SLT products was less in SLT 
users (<43%). In the focused group discussion, 
they expressed no intention for cessation and 
lack of knowledge on SLT product adverse effect 
13. Consumption of SLT products by pulmonary 
tuberculosis (TB) patients is associated with 
worsening the condition of TB patients and leads 
to an increase in the death rate 34. 
 
 
 
Figure 2: Comparison of SLT dependence & willingness to quit with international and GATS-2 re-
port. (a)  No statistical significance in the SLT dependence in patients between 5-year data of na-
tional and international survey/ publication. (b) No statistical significance was observed in willing-
ness to quit SLT within a 12-month period captured from last 5-year data of national and international 
published data and in comparison with GATS-2 fact sheet report. The data presented here is in 
percent mean and standard deviation. 
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In India, the nicotine content in the SLT products 
marketed have a much varied range from 1.0 to 
50.0 mg/ gm. There is no compliance in the pol-
icy and regulation for bringing resolution of nico-
tine content. Nicotine content in the tobacco 
products plays a major role in the addiction 
which persistently regulates access to any form 
of tobacco products, effectiveness of the to-
bacco controlling interventions and policies face 
hardships in taking the measure of cessation 35. 
Factors connected to SLT consumption in day to 
day lives are literacy rate, work related practice 
and acceptance of the SLT product/ users 
among society/ work environment. However, the 
majority of the SLT users (90%) preferred to quit 
and were recognized with a higher score of quit 
attempts in the daily activity but found no ob-
struction in the usage of SLT products from so-
ciety, company policies or law enforcement 36. 
The tobacco dependence study assessing and 
evaluating for the accuracy of the self-reports 
given by SLT users by using double-blind pla-
cebo-controlled clinical trials revealed 34.1% of 
SLT users under-reported the tobacco use in 
nicotine dependence medication by varenicline 
37, 38.  
Discussion 
According to the statistics provided by the Food 
and Agriculture Organization of the United Na-
tion, India is the third-largest producer of tobacco 
globally 2, 39. WHO-FCTC global reports on to-
bacco dependence and cessation programs im-
plemented by 69% parties of FCTC members- 
by excelling in health, tobacco control and edu-
cational plans and programs. FCTC revealed 
that the lack of relevant recent data on smoke-
less tobacco products causes a hindrance in the 
execution of tobacco product cessation 40. Ac-
cording to a household survey conducted by the 
National Cancer Institute and Centers for Dis-
ease Control and Prevention, around 80% of 290 
million people (232 million) were SLT users 2. 
SEAR regions have a high prevalence of SLT 
use with a wide variety of SLT product options 
for SLT users to switch to, the most popular 
products considered are gutkha, pan-masala, 
mawa, mishri, snus and khaini 3.  
Healthcare based cross-sectional study con-
ducted in the Western part of India reveals 258 
SLT users have a higher dependence rate (20%) 
with a 61% of willingness to quit SLT products. 
The healthcare professionals illustrate that occu-
pation related stress and travelling is counter-
balanced by using SLT products especially in il-
literates 31. As per Divinakumar et al, 41% of to-
bacco product users and 750 SLT users have a 
history of lower literacy rate, occupation associ-
ated with travelling, family history of tobacco 
uses and alcohol consumption. Tobacco product 
users (20%) have a higher prevalence of nico-
tine dependency (72%) and a large percentage 
of them (52.9%) attempted to quit tobacco more 
than once in life 32. 
Nicotine, a reversible agonist of neuronal nico-
tinic acetylcholine receptors (nAChRs) causes 
stimulation similar to various neurotransmitters 
such as noradrenaline, acetylcholine (Ach), 
gamma‑aminobutyric acid, dopamine and gluta-
mate. The activation of nAChR receptors en-
hance number of physiological and metabolic 
processes such as anxiety, nociception, learn-
ing, memory, attentiveness and locomotion 
leads to the alleviation of stress in the brain and 
causes addiction. Nicotine addiction, a chronic 
condition of tobacco product use, encourages 
users to make an attempt of tobacco use over 
time and prevents them from quitting tobacco 
products. Nicotine, being the main constituent of 
tobacco products, is directly linked to addiction. 
Many studies have been conducted to prove the 
addiction toward nicotine by FTND score 
through self-report of the survey and/or health 
professional counselling, but chances of under-
reporting tobacco dependence, quit and cessa-
tion is common. Hence the self-report and sur-
vey program should support evidence and vali-
dation-based reports from the SLT users in the 
cessation program 37.  
According to Article 14, the first importance is 
given to the guidance for the development of 
basic infrastructure on treatment and stress. 
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Secondly, evidence-based approach for the 
treatment of tobacco cessation through clinical 
trial and observation must be given prominence. 
The practice for tobacco dependence and ces-
sation by taking the effective step through scien-
tific evidence (survey) of users, and conse-
quently suggesting counselling and regular fol-
low-up by mobile or any other mode 6, 7, 16. Price 
and taxation measures on tobacco products 
contribute to better outcomes with more stimulus 
in the program of quitting tobacco and its de-
pendence 41. High endurance and well-struc-
tured FCTC articles on tobacco dependence re-
duction and cessation measures are not fully im-
plemented for SLT cessation like those for smok-
ing tobacco. Tobacco cessation interventions for 
youths are established by using a small number 
of studies that are difficult in concluding the ex-
act behavioral interventions and pharmacother-
apy in developed and developing countries 42. 
Twenty case-controlled clinical trials (16-USA; 3-
India & Sweden) were conducted with more than 
28000 SLT users during the period of 1992-2017 
given behavioral intervention. It was efficiently 
promoted through self-help guide, videos, moti-
vational interviews, counselling (telephonic), 
athletic trainer referral, nicotine replacement 
therapy (NRT), pharmacotherapy, non-nicotine 
therapy, etc. It was finalized with proper follow-
up of about 3-6 months for counselling and oral 
examination considered for efficient success of 
the advanced intervention 6, 16, 30. 
Tobacco cessation intervention and strategies 
are available and applied specifically to control 
smoking tobacco. The setback of SLT cessation 
and intervention is specifically due to cultural/ 
societal acceptance, limited knowledge on SLT 
harmfulness and potential habituation/ addiction. 
The results of current review matches to the 
GATS-2 report on quit attempts (33.2%) by SLT 
users in a 12-month period. From this fact, it is 
clear that SLT users have the high intention of 
addictiveness towards SLT products 1. The high 
nicotine content in the SLT products with no en-
forcement barriers accounts for much of the ad-
diction. 
Further, the pharmacotherapy intervention in the 
SLT cessation program seems to be less effec-
tive. An evaluation of varenicline efficacy on SLT 
users in a double-blind placebo-controlled trial 
showed no significance between control and 
varenicline treated users 38. In the case of nico-
tine replacement therapy and bupropion, the to-
bacco quitting attempts are high in comparison 
with placebo. But the pharmacotherapy interven-
tions are more successful in smoking tobacco 
than chewing tobacco 41, 43. By reducing targeted 
demand and disturbing the SLT use by improv-
ing the education, motivating the SLT users to 
quit and legalizing the SLT cessation programs 
in the workstation and in communities might help 
promote SLT cessation. In India around 429 to-
bacco cessation facilities are available in 31 
states/ provinces 8, which has to increase to get 
better management of the cessation program. 
The number of the programs conducted in the 
past 5 years are quite limited and not covered in 
different parts of the country. However, the study 
came with multiple issues for tobacco depend-
ence and cessation and it may give robust infor-
mation on the outline of the concerns. 
Conclusion 
The looming threat of SLT products across the 
world needs to encourage evidence-based re-
search with scientific proof in low-income and 
middle-income countries of SEAR. The policies 
and regulations of WHO-FCTC need to be im-
plemented by each of the ruling parties of the 
member countries. SLT products cessation pro-
gram and policies in India are efficiently dis-
cussed only at the proposal level. Concluding 
with the pathetic condition of the execution of the 
aforementioned policies, it has to be imple-
mented as effectively as policies to curb use of 
smoking tobacco. There are lots of lacunae in 
the SLT dependence and cessation interven-
tions in Indian practice. Being a major consumer 
of SLT products globally, the odd challenges are 
yet to be identified in addressing the WHO-
FCTC Article 14 policies in India for controlling 
SLT dependence and cessation. New ap-
proaches have to be integrated with behavioral 
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interventions for the feasible advancement in 
SLT cessation starting from self-help guidance, 
at the healthcare provider level, counselling, fol-
low-up, training, pharmacotherapy, school cam-
paigning, etc. The key approach has to be of rec-
ommendation from the international, national 
and sub-regional manufacturer, seller, etc., all 
the interventions have to take part in controlling 
SLT products. Strong regulation needs to be em-
ployed for the standardized formulation of SLT 
products with the content disclosure specifically 
for nicotine (total alkaloids) and TSNA contents. 
The availability, low cost and accessibility of SLT 
products have led to a high rate of abuse, and 
this should be immediately controlled by increas-
ing the taxation and pricing. This shall reduce the 
dependence and improve cessation among SLT 
users by reducing the affordability as per Article 
6 in demand for reduction measures of tobacco. 
According to FCTC Article 11 packing and label-
ling of the SLT need to follow with the weight of 
evidence by targeting regional/ national resident 
based necessity. Healthcare providers should 
approach SLT users with appropriate knowledge 
to guide the users to quit tobacco products, by 
providing behavioral interventions with the 
proper suggestion of follow-up and counselling 
sessions. The government policies with proac-
tive initiatives for smoking tobacco control imple-
mentation also have to reciprocate the same at-
tention for SLT products. 
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